Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.
The company's flagship products include:
- Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
- Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
- Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
- Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
- Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).
Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.
Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.
In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.
Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.
Guardant Health (Nasdaq: GH) announced Medicare coverage expansion for its Guardant Reveal test through Palmetto GBA. The coverage now includes surveillance testing for colorectal cancer (CRC) patients following curative intent therapy, expanding from the previous early post-surgical setting coverage.
The Guardant Reveal, running on the Smart Liquid Biopsy platform, is a blood-based test that uses epigenomic analysis to detect circulating tumor DNA (ctDNA) for minimal residual disease (MRD) monitoring. This tissue-free approach addresses the needs of cancer patients without available tissue specimens or those for whom tissue collection is challenging.
Of the 18 million cancer patients in the U.S. who could benefit from MRD testing, less than 3% currently receive it. Over 12 million cancer patients are more than five years post-surgery, making tissue specimen collection difficult, and over three million patients have no tumor tissue available.
Guardant Health (GH) and ConcertAI have announced a collaboration to create the first multi-modal real-world data solution that integrates comprehensive patient electronic medical records with genomic and epigenomic tumor profiling information across cancer care. The partnership combines ConcertAI's database of 5.5M clinical records with Guardant's profiling data across 60+ tumor types.
The integrated platform will provide biopharmaceutical companies access to extensive data including methylation data from Guardant Infinity smart liquid biopsy platform, helping researchers better understand disease biology, identify drivers of tumor evolution, and study resistance mechanisms. The solution covers the entire cancer care spectrum, from monitoring residual disease in early-stage cancer to treatment selection in advanced cases.
This collaboration aims to accelerate cancer therapy research and development by providing unprecedented insights into patient cancer journeys and tumor interactions. Financial terms of the agreement were not disclosed.
Viz.ai and Guardant Health (GH) announced a proposed collaboration to improve lung cancer care through the integration of AI and genomic insights. The partnership aims to address the critical issue that approximately 40% of lung cancer patients do not receive guideline-directed medical therapy.
The collaboration will focus on facilitating timely biomarker testing using Guardant360® CDx liquid biopsy, accelerating precision diagnosis and treatment selection. Viz.ai's platform, currently implemented in 1,700 hospitals, uses machine learning to analyze imaging data, EHR, and other tests to provide real-time insights and automated assessments.
This initiative aims to tackle delays in diagnosis, testing, and treatment that can lead to cancer progression and higher mortality rates. The partnership combines Viz.ai's AI-powered disease detection capabilities with Guardant Health's precision oncology expertise to streamline the patient journey and improve outcomes.
Guardant Health (GH) reported strong preliminary Q4 and full-year 2024 results, with total revenue reaching approximately $200 million in Q4 (29% increase) and $737 million for the full year (31% increase). The company saw significant growth in test volumes, with 57,300 oncology clinical tests (24% increase) and 11,050 biopharma tests (16% increase) in Q4.
The Shield screening program reported approximately 6,400 tests with revenue of $4 million. For the full year, the company conducted 206,700 oncology clinical tests and 40,500 biopharma tests, showing increases of 20% and 35% respectively. Free cash flow was negative $84 million in Q4 and negative $275 million for 2024. The company maintained a strong cash position of $944 million as of December 31, 2024.
Guardant Health (Nasdaq: GH) announced its Shield™ multi-cancer detection (MCD) test has been selected by the National Cancer Institute (NCI) for inclusion in the Vanguard study. The selection was based on the platform's strong performance in detecting various cancer types and predicting cancer tissue origin.
The Vanguard study is a four-year pilot initiative by the NCI's Cancer Screening Research Network (CSRN) that will enroll up to 24,000 people to inform the design of a larger randomized controlled trial evaluating MCD tests for cancer screening. Guardant Health was chosen as one of only two participants after evaluation of multiple companies.
The study will assess the Shield platform's performance in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric cancers. Results from the NCI verification study are expected in early 2025.
Guardant Health (Nasdaq: GH), a leading precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team will deliver a presentation followed by a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.
Interested investors and stakeholders can access both live and archived webcasts of the sessions through the 'Investors' section of Guardant Health's official website at www.guardanthealth.com.
Guardant Health (Nasdaq: GH) and Meaningful Insights Biotech Analytics (MiBA) have announced a strategic partnership to enhance precision oncology through biomarker testing and data analytics. The collaboration combines MiBA's AI technologies and oncology data with Guardant's expertise in tumor profiling and circulating tumor DNA monitoring.
The partnership aims to transform cancer care by implementing personalized, data-driven approaches that improve access to innovative treatments. The initiative will provide healthcare stakeholders with knowledge about biomarker testing, cancer recurrence monitoring tools, and data insights throughout the care continuum, ultimately improving cancer patient care standards.
COTA and Guardant Health (Nasdaq: GH) announced a partnership to combine their oncology data resources for advancing precision cancer therapy development. The collaboration merges COTA's research-grade EHR data from academic and community care centers with Guardant's clinicogenomic testing data.
This partnership aims to help researchers better understand correlations between molecular biomarkers, treatments, and clinical outcomes. The combined dataset and AI analytics will support more efficient drug development, particularly given that 97% of cancer clinical trials fail and development can take up to fifteen years.
The collaboration expands COTA's data breadth into solid tumors, focusing on lung, breast, and colorectal cancers. Guardant's data covers all disease stages, from initial tumor profiling to therapy monitoring, while COTA's data tracks complete cancer care journeys.
Guardant Health (Nasdaq: GH) announced a collaboration with Boehringer Ingelheim to develop the Guardant360® CDx liquid biopsy as a companion diagnostic for zongertinib, an investigational treatment for non-small cell lung cancer (NSCLC). The blood test will identify NSCLC patients with HER2 mutations who may benefit from zongertinib treatment.
According to Guardant Health's chairman, approximately 40,000 people worldwide are diagnosed annually with NSCLC with HER2 mutations, who often respond poorly to standard treatments. The Guardant360 CDx is already FDA-approved for comprehensive liquid biopsy in advanced solid tumors and serves as a companion diagnostic for multiple NSCLC targeted therapies and breast cancer therapy targeting ESR1 mutations.
Guardant Health (Nasdaq: GH) announced upcoming presentations at the San Antonio Breast Cancer Symposium (SABCS) 2024, showcasing research on their liquid biopsy tests and AI analytics. The company will present eight posters, including a spotlight presentation on the Guardant Reveal test, which investigates circulating tumor DNA (ctDNA) dynamics in breast cancer treatment.
The research suggests that ctDNA analysis could help predict endocrine therapy sensitivity and long-term outcomes in HR+ breast cancer. The presentations will cover various topics including molecular profiling, minimal residual disease testing, and real-world data analysis using Guardant's products such as GuardantINFORM, Guardant Infinity, Guardant360 CDx, and Guardant Reveal.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
What does Guardant Health, Inc. specialize in?
What are the main products offered by Guardant Health?
What is Guardant360 CDx?
How does Guardant Health support cancer research?
What is the significance of the Reveal test?
What is the purpose of the Shield test?
Who are some of the major investors in Guardant Health?
Where is Guardant Health, Inc. headquartered?
What is the Guardant360 LDT test used for?
How does Guardant Health contribute to early cancer detection?
